Skip to main content
Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics 4/2012

01.12.2012 | Original Paper

Bioavailability and in vivo efficacy of a praziquantel–polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice

verfasst von: Naglaa El-Lakkany, Sayed Hassan Seif el-Din, Lamia Heikal

Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

One of the problems of praziquantel (PZQ) is its very low aqueous solubility. Moreover, its dissolution rate is considered the limiting factor for its bioavailability. This work correlates the physical properties and the dissolution behavior of PZQ–polyvinylpyrrolidone (PVP) solid dispersion (SD) at the ratios of 1:1 and 3:7 with its oral bioavailability and its in vivo efficacy against Schistosoma mansoni (S. mansoni). The PZQ and PZQ–PVP SD were characterized by infrared spectroscopy, differential scanning calorimetry, scanning electron microscopy (SEM) and solubility test. Results showed a decrease in crystallinity, possible interaction between PZQ and PVP, greater increase in dissolution rate and appreciable reduction in particle size. S. mansoni-infected mice treated orally with either pure PZQ or PZQ–PVP at a single dose of 500 mg/kg showed a higher increase in AUC(0–8h), C max, K a and t 1/2e with a significant decrease in k el versus the corresponding uninfected mice. Moreover, uninfected and infected mice treated with PZQ–PVP SD showed 2.3-, 1.6- and 1.3-, 1.25-fold increase, respectively, in AUC(0–8h) and C max, with a decrease in k el and increase in t 1/2e by twofold versus the corresponding pure PZQ-treated groups. Percentage worm reduction at all administered doses (62.5, 125, 250, 500 and 1,000 mg/kg) was significantly higher (1- to 1.5-fold) in mice treated with PZQ–PVP SD (ED50 = 40.92) versus those treated with pure PZQ (ED50 = 99.29). In addition, a significant reduction in total tissue egg load concomitant with a significant decrease in total immature and mature eggs and an increase in dead eggs in PZQ–PVP SD-treated groups versus their corresponding pure PZQ-treated groups was recorded. Solid dispersion of PZQ with PVP could lead to a further improvement in the effectiveness of PZQ therapy especially with the appearance of some PZQ-tolerant S. mansoni isolates.
Literatur
Zurück zum Zitat Akbarieh M, Besner JG, Galal A, Tawashi R (1992) Liposomal system for the targeting and controlled release of praziquantel. Drug Dev Ind Pharm 18:303–317CrossRef Akbarieh M, Besner JG, Galal A, Tawashi R (1992) Liposomal system for the targeting and controlled release of praziquantel. Drug Dev Ind Pharm 18:303–317CrossRef
Zurück zum Zitat Andrews P (1976) Pharmacokinetic studies with Droncit in animals using a biological assay. Vet Med Rev 2:154–165 (English Edition) Andrews P (1976) Pharmacokinetic studies with Droncit in animals using a biological assay. Vet Med Rev 2:154–165 (English Edition)
Zurück zum Zitat Andrews P, Dycka J, Frank G (1980) Effect of praziquantel on clinical chemical parameters in healthy and schistosome-infected mice. Ann Trop Med Parasitol 74:167–177PubMed Andrews P, Dycka J, Frank G (1980) Effect of praziquantel on clinical chemical parameters in healthy and schistosome-infected mice. Ann Trop Med Parasitol 74:167–177PubMed
Zurück zum Zitat Badawi AF, Mostafa MH (1993) Possible mechanisms of alteration in the capacity of carcinogen-metabolizing enzymes during schistosomiasis. J Int Med Res 21:281–305PubMed Badawi AF, Mostafa MH (1993) Possible mechanisms of alteration in the capacity of carcinogen-metabolizing enzymes during schistosomiasis. J Int Med Res 21:281–305PubMed
Zurück zum Zitat Botros SS, Seif el-Din SH, El-Lakkany NM, Sabra AA, Ebeid FA (2006) Drug metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities. J Parasitol 92:1344–1349PubMedCrossRef Botros SS, Seif el-Din SH, El-Lakkany NM, Sabra AA, Ebeid FA (2006) Drug metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities. J Parasitol 92:1344–1349PubMedCrossRef
Zurück zum Zitat Botros S, El-Lakkany N, Seif el-Din SH, Sabra A, Ibrahim M (2011) Comparative efficacy and bioavailability of different praziquantel brands. Exp Parasitol 127:515–521PubMedCrossRef Botros S, El-Lakkany N, Seif el-Din SH, Sabra A, Ibrahim M (2011) Comparative efficacy and bioavailability of different praziquantel brands. Exp Parasitol 127:515–521PubMedCrossRef
Zurück zum Zitat Brant PC, Prata A (1979) Altered drug metabolism in hepatosplenic schistosomiasis. Rev Inst Med Trop Sao Paulo 21:254–259PubMed Brant PC, Prata A (1979) Altered drug metabolism in hepatosplenic schistosomiasis. Rev Inst Med Trop Sao Paulo 21:254–259PubMed
Zurück zum Zitat Caffrey CR (2007) Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 11:433–439PubMedCrossRef Caffrey CR (2007) Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 11:433–439PubMedCrossRef
Zurück zum Zitat Cheever AW (1968) Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues. Bull World Health Organ 39:328–331PubMed Cheever AW (1968) Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues. Bull World Health Organ 39:328–331PubMed
Zurück zum Zitat Chiou WL, Riegelman S (1969) Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. J Pharm Sci 58:1505–1510PubMedCrossRef Chiou WL, Riegelman S (1969) Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. J Pharm Sci 58:1505–1510PubMedCrossRef
Zurück zum Zitat Chiou WL, Riegelman S (1971) Pharmaceutical applications of solid dispersion systems. J Pharm Sci 60:1281–1302PubMedCrossRef Chiou WL, Riegelman S (1971) Pharmaceutical applications of solid dispersion systems. J Pharm Sci 60:1281–1302PubMedCrossRef
Zurück zum Zitat Cioli D, Botros S, Wheatcroft-Franklow K, Mbaye A, Southgate V, Tchuem-Tchuente L, Pica-Mattoccia L, Troiani AR, Seif el-Din S, Sabra A, Albin J, Engels D, Doenhoff M (2004) Determination of ED50 values for praziquantel in praziquantel-resistant and susceptible Schistosoma mansoni isolates. Int J Parasitol 34:979–987PubMedCrossRef Cioli D, Botros S, Wheatcroft-Franklow K, Mbaye A, Southgate V, Tchuem-Tchuente L, Pica-Mattoccia L, Troiani AR, Seif el-Din S, Sabra A, Albin J, Engels D, Doenhoff M (2004) Determination of ED50 values for praziquantel in praziquantel-resistant and susceptible Schistosoma mansoni isolates. Int J Parasitol 34:979–987PubMedCrossRef
Zurück zum Zitat Corrigan OI, Holohan EM (1984) Amorphous spray-dried hydroflumethiazide-polyvinylpyrrolidone systems: physiochemical properties. J Pharm Pharmacol 36:217–221PubMedCrossRef Corrigan OI, Holohan EM (1984) Amorphous spray-dried hydroflumethiazide-polyvinylpyrrolidone systems: physiochemical properties. J Pharm Pharmacol 36:217–221PubMedCrossRef
Zurück zum Zitat Corrigan OI, Timoney RF (1975) The influence of polyvinylpyrrolidone on the dissolution properties of hydroflumethiazide. J Pharm Pharmacol 27:759–764PubMedCrossRef Corrigan OI, Timoney RF (1975) The influence of polyvinylpyrrolidone on the dissolution properties of hydroflumethiazide. J Pharm Pharmacol 27:759–764PubMedCrossRef
Zurück zum Zitat Craig DQM (2002) The mechanism of drug release from solid dispersion in water-soluble polymers. Int J Pharm 231:131–144PubMedCrossRef Craig DQM (2002) The mechanism of drug release from solid dispersion in water-soluble polymers. Int J Pharm 231:131–144PubMedCrossRef
Zurück zum Zitat Doenhoff MJ, Cioli D, Utzinger J (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21:659–667PubMedCrossRef Doenhoff MJ, Cioli D, Utzinger J (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21:659–667PubMedCrossRef
Zurück zum Zitat Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, Coles G, Tchuem Tchuenté LA, Mbaye A, Engels D (2009) Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 136:1825–1835PubMedCrossRef Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, Coles G, Tchuem Tchuenté LA, Mbaye A, Engels D (2009) Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 136:1825–1835PubMedCrossRef
Zurück zum Zitat Duvall RH, De Witt WB (1967) Technique for recovering adult schistosomes from laboratory animals. Am J Trop Med Hyg 16:438–486 Duvall RH, De Witt WB (1967) Technique for recovering adult schistosomes from laboratory animals. Am J Trop Med Hyg 16:438–486
Zurück zum Zitat Ebeid FA, Seif el-Din SH, Ezzat AR (2000) Effect of Schistosoma mansoni infection and treatment on drug-metabolizing enzymes. Arzneimittelforschung 50:867–874PubMed Ebeid FA, Seif el-Din SH, Ezzat AR (2000) Effect of Schistosoma mansoni infection and treatment on drug-metabolizing enzymes. Arzneimittelforschung 50:867–874PubMed
Zurück zum Zitat El-Arini SK, Leuenberger H (1998) Dissolution properties of praziquantel-PVP systems. Pharm Acta Helv 73:89–94PubMedCrossRef El-Arini SK, Leuenberger H (1998) Dissolution properties of praziquantel-PVP systems. Pharm Acta Helv 73:89–94PubMedCrossRef
Zurück zum Zitat El-Guiniady MA, El-Touny MA, Abdel-Bary MA, Abdel-Fatah SA, Metwally AA (1994) Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. Am J Trop Med Hyg 51:809–818PubMed El-Guiniady MA, El-Touny MA, Abdel-Bary MA, Abdel-Fatah SA, Metwally AA (1994) Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. Am J Trop Med Hyg 51:809–818PubMed
Zurück zum Zitat El-Lakkany NM, Seif el-Din SH, Badawy AA, Ebeid FA (2004) Effect of artemether alone and in combination with grapefruit juice on hepatic drug-metabolizing enzymes and biochemical aspects in experimental Schistosoma mansoni. Int J Parasitol 34:1405–1412PubMedCrossRef El-Lakkany NM, Seif el-Din SH, Badawy AA, Ebeid FA (2004) Effect of artemether alone and in combination with grapefruit juice on hepatic drug-metabolizing enzymes and biochemical aspects in experimental Schistosoma mansoni. Int J Parasitol 34:1405–1412PubMedCrossRef
Zurück zum Zitat Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH (2003) Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 19:509–515PubMedCrossRef Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH (2003) Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 19:509–515PubMedCrossRef
Zurück zum Zitat Franco M, Trapani G, Latrofa A, Tullio C, Provenzano MR, Serra M, Muggironi M, Biggio G, Liso G (2001) Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and -polyvinylpyrrolidone K-30 solid dispersions. Int J Pharm 225:63–73PubMedCrossRef Franco M, Trapani G, Latrofa A, Tullio C, Provenzano MR, Serra M, Muggironi M, Biggio G, Liso G (2001) Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and -polyvinylpyrrolidone K-30 solid dispersions. Int J Pharm 225:63–73PubMedCrossRef
Zurück zum Zitat Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker Inc., New York Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker Inc., New York
Zurück zum Zitat Gonnert R, Andrews P (1977) Praziquantel, a new broad-spectrum antischistosomal agent. Z Parasitenkd 52:129–150PubMedCrossRef Gonnert R, Andrews P (1977) Praziquantel, a new broad-spectrum antischistosomal agent. Z Parasitenkd 52:129–150PubMedCrossRef
Zurück zum Zitat Hong ST, Lee SH, Lee SJ, Kho WG, Lee M, Li S, Chung BS, Seo M, Choi MH (2003) Sustained-release praziquantel tablet: pharmacokinetics and the treatment of clonorchiasis in beagle dogs. Parasitol Res 91:316–320PubMedCrossRef Hong ST, Lee SH, Lee SJ, Kho WG, Lee M, Li S, Chung BS, Seo M, Choi MH (2003) Sustained-release praziquantel tablet: pharmacokinetics and the treatment of clonorchiasis in beagle dogs. Parasitol Res 91:316–320PubMedCrossRef
Zurück zum Zitat Kim KH, Frank MJ, Henderson NL (1985) Application of differential scanning calorimetry to the study of solid drug dispersions. J Pharm Sci 74:283–289PubMedCrossRef Kim KH, Frank MJ, Henderson NL (1985) Application of differential scanning calorimetry to the study of solid drug dispersions. J Pharm Sci 74:283–289PubMedCrossRef
Zurück zum Zitat Leopold G, Ungethum W, Groll E, Diekmann HW, Nowak H, Wegner DH (1978) Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. Eur J Clin Pharmacol 14:281–291PubMedCrossRef Leopold G, Ungethum W, Groll E, Diekmann HW, Nowak H, Wegner DH (1978) Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. Eur J Clin Pharmacol 14:281–291PubMedCrossRef
Zurück zum Zitat Li X-Q, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM (2003) Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59:429–442PubMedCrossRef Li X-Q, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM (2003) Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59:429–442PubMedCrossRef
Zurück zum Zitat Liang YS, John BI, Boyd DA (1987) Laboratory cultivation of schistosome vector snails and maintenance of schistosome life cycles. Proceeding of the 1st Sino-American. Symposium 1:34–48 Liang YS, John BI, Boyd DA (1987) Laboratory cultivation of schistosome vector snails and maintenance of schistosome life cycles. Proceeding of the 1st Sino-American. Symposium 1:34–48
Zurück zum Zitat Liang YS, Coles GC, Doenhoff MJ, Southgate VR (2001) In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel. Int J Parasitol 31:1227–1235PubMedCrossRef Liang YS, Coles GC, Doenhoff MJ, Southgate VR (2001) In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel. Int J Parasitol 31:1227–1235PubMedCrossRef
Zurück zum Zitat Lopez-Garcia ML, Torrado-Duran S, Torrado-Duran J, Martínez-Fernández AR, Bolás-Fernández F (1997) Albendazole versus ricobendazole (albendazole-sulphoxide) against enteral and parenteral stages of Trichinella spiralis in mice. Int J Parasitol 27:781–785PubMedCrossRef Lopez-Garcia ML, Torrado-Duran S, Torrado-Duran J, Martínez-Fernández AR, Bolás-Fernández F (1997) Albendazole versus ricobendazole (albendazole-sulphoxide) against enteral and parenteral stages of Trichinella spiralis in mice. Int J Parasitol 27:781–785PubMedCrossRef
Zurück zum Zitat Mandour ME, El-Turabi H, Homeida MM, El-Sadig T, Ali HM, Bennett JL, Leahey WJ, Harron DW (1990) Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans R Soc Trop Med Hyg 84:389–393PubMedCrossRef Mandour ME, El-Turabi H, Homeida MM, El-Sadig T, Ali HM, Bennett JL, Leahey WJ, Harron DW (1990) Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans R Soc Trop Med Hyg 84:389–393PubMedCrossRef
Zurück zum Zitat Metwally AA (1989) Pharmacokinetics of praziquantel in schistosomiasis patients. Egypt J Bilharz 11:133–143 Metwally AA (1989) Pharmacokinetics of praziquantel in schistosomiasis patients. Egypt J Bilharz 11:133–143
Zurück zum Zitat Meyer T, Sekljic H, Fuchs S, Bothe H, Schollmeyer D, Miculka C (2009) Taste, a new incentive to switch to (R)-Praziquantel in schistosomiasis treatment. PLoS Negl Trop Dis 3:e357PubMedCrossRef Meyer T, Sekljic H, Fuchs S, Bothe H, Schollmeyer D, Miculka C (2009) Taste, a new incentive to switch to (R)-Praziquantel in schistosomiasis treatment. PLoS Negl Trop Dis 3:e357PubMedCrossRef
Zurück zum Zitat Ozdemir N, Ordu S (1997) Dissolution rate of furosemide from polyethylene glycol solid dispersions. Farmaco 52:625–629PubMed Ozdemir N, Ordu S (1997) Dissolution rate of furosemide from polyethylene glycol solid dispersions. Farmaco 52:625–629PubMed
Zurück zum Zitat Pellegrino J, Oliveira CA, Faria J, Cunah AS (1962) New approach to the screening of drugs in experimental schistosomiasis mansoni in mice. Am J Trop Med Hyg 11:201–215PubMed Pellegrino J, Oliveira CA, Faria J, Cunah AS (1962) New approach to the screening of drugs in experimental schistosomiasis mansoni in mice. Am J Trop Med Hyg 11:201–215PubMed
Zurück zum Zitat Shefter E, Cheng KC (1980) Drug-Polyvinylpyrrolidone (PVP) dispersions: a differential scanning colorimetric study. Int J Pharm 6:179–182CrossRef Shefter E, Cheng KC (1980) Drug-Polyvinylpyrrolidone (PVP) dispersions: a differential scanning colorimetric study. Int J Pharm 6:179–182CrossRef
Zurück zum Zitat Sheu MT, Yeh CM, Sokoloski TD (1994) Characterization and dissolution of fenofibrate solid dispersion systems. Int J Pharm 103:137–146CrossRef Sheu MT, Yeh CM, Sokoloski TD (1994) Characterization and dissolution of fenofibrate solid dispersion systems. Int J Pharm 103:137–146CrossRef
Zurück zum Zitat Sheweita SA, Mangoura SA, El-Shemi AG (1998) Different levels of Schistosoma mansoni infection induced changes in drug-metabolizing enzymes. J Helminthol 72:71–77PubMedCrossRef Sheweita SA, Mangoura SA, El-Shemi AG (1998) Different levels of Schistosoma mansoni infection induced changes in drug-metabolizing enzymes. J Helminthol 72:71–77PubMedCrossRef
Zurück zum Zitat Simonelli AP, Metha SC, Higuchi WI (1969) Dissolution rates of high-energy polyvinylpirrolidone-PVP-sulfathiazole coprecipitates. J Pharm Sci 58:538–549PubMedCrossRef Simonelli AP, Metha SC, Higuchi WI (1969) Dissolution rates of high-energy polyvinylpirrolidone-PVP-sulfathiazole coprecipitates. J Pharm Sci 58:538–549PubMedCrossRef
Zurück zum Zitat Simonelli AP, Mehta SC, Higuchi WI (1976) Dissolution rates of high-energy sulfathiazole-povidone coprecipitates. II: characterization of form of drug controlling its dissolution rate via solubility studies. J Pharm Sci 65:355–361PubMedCrossRef Simonelli AP, Mehta SC, Higuchi WI (1976) Dissolution rates of high-energy sulfathiazole-povidone coprecipitates. II: characterization of form of drug controlling its dissolution rate via solubility studies. J Pharm Sci 65:355–361PubMedCrossRef
Zurück zum Zitat Susumu H, Takeshi H, Naho F, Akira K, Etsuo Y, Katsuhide T (2005) Effects of water content in physical mixture and heating temperature on crystallinity of troglitazone-PVP K30 solid dispersions prepared by closed melting method. Int J Pharm 302:103–112CrossRef Susumu H, Takeshi H, Naho F, Akira K, Etsuo Y, Katsuhide T (2005) Effects of water content in physical mixture and heating temperature on crystallinity of troglitazone-PVP K30 solid dispersions prepared by closed melting method. Int J Pharm 302:103–112CrossRef
Zurück zum Zitat Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S (1996) Properties of solid dispersions of piroxicam in polyvinylpyrrolidone K-30. Int J Pharm 143:59–66CrossRef Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S (1996) Properties of solid dispersions of piroxicam in polyvinylpyrrolidone K-30. Int J Pharm 143:59–66CrossRef
Zurück zum Zitat Taylor LS, Zografi G (1997) Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 14:1691–1698PubMedCrossRef Taylor LS, Zografi G (1997) Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 14:1691–1698PubMedCrossRef
Zurück zum Zitat Tekwanl BL, Shukla OP, Ghatak S (1988) Altered drug metabolism in parasitic diseases. Parasitol Today 4:4–10PubMedCrossRef Tekwanl BL, Shukla OP, Ghatak S (1988) Altered drug metabolism in parasitic diseases. Parasitol Today 4:4–10PubMedCrossRef
Zurück zum Zitat Torrado S, Torrado S, Torrado JJ, Cadorniga R (1996) Preparation, dissolution and characterization of albendazole solid dispersions. Int J Pharm 140:247–250CrossRef Torrado S, Torrado S, Torrado JJ, Cadorniga R (1996) Preparation, dissolution and characterization of albendazole solid dispersions. Int J Pharm 140:247–250CrossRef
Zurück zum Zitat Torre P, Torrado S, Torrado S (1999) Preparation, dissolution and characterization of praziquantel solid dispersions. Chem Pharm Bull 47:1629–1633CrossRef Torre P, Torrado S, Torrado S (1999) Preparation, dissolution and characterization of praziquantel solid dispersions. Chem Pharm Bull 47:1629–1633CrossRef
Zurück zum Zitat Van den Mooter G, Augustijns P, Blaton N, Kinget R (1998) Physicochemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. Int J Pharm 164:67–80CrossRef Van den Mooter G, Augustijns P, Blaton N, Kinget R (1998) Physicochemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. Int J Pharm 164:67–80CrossRef
Zurück zum Zitat William S, Botros S (2004) Validation of sensitivity to praziquantel using Schistosoma mansoni worm muscle tension and Ca2+-uptake as possible in vitro correlates to in vivo ED50 determination. Int J Parasitol 34:971–977PubMedCrossRef William S, Botros S (2004) Validation of sensitivity to praziquantel using Schistosoma mansoni worm muscle tension and Ca2+-uptake as possible in vitro correlates to in vivo ED50 determination. Int J Parasitol 34:971–977PubMedCrossRef
Zurück zum Zitat William S, Botros S, Ismail M, Farghally A, Day TA, Bennett JL (2001a) Praziquantel-induced tegumental damage in vitro is diminished in schistosomes derived from praziquantel-resistant infections. Parasitology 122:63–66PubMedCrossRef William S, Botros S, Ismail M, Farghally A, Day TA, Bennett JL (2001a) Praziquantel-induced tegumental damage in vitro is diminished in schistosomes derived from praziquantel-resistant infections. Parasitology 122:63–66PubMedCrossRef
Zurück zum Zitat William S, Sabra A, Ramzy F, Mousa M, Demerdash Z, Bennett J, Day TA, Botros S (2001b) Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel. Int J Parasitol 31:1093–1100PubMedCrossRef William S, Sabra A, Ramzy F, Mousa M, Demerdash Z, Bennett J, Day TA, Botros S (2001b) Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel. Int J Parasitol 31:1093–1100PubMedCrossRef
Zurück zum Zitat Xiao SH, Catto BA, Webster LT (1983) Quantitative determination of praziquantel in serum by high performance liquid chromatography. J Chromatogr 275:127–132PubMedCrossRef Xiao SH, Catto BA, Webster LT (1983) Quantitative determination of praziquantel in serum by high performance liquid chromatography. J Chromatogr 275:127–132PubMedCrossRef
Metadaten
Titel
Bioavailability and in vivo efficacy of a praziquantel–polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice
verfasst von
Naglaa El-Lakkany
Sayed Hassan Seif el-Din
Lamia Heikal
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Drug Metabolism and Pharmacokinetics / Ausgabe 4/2012
Print ISSN: 0378-7966
Elektronische ISSN: 2107-0180
DOI
https://doi.org/10.1007/s13318-012-0089-6

Weitere Artikel der Ausgabe 4/2012

European Journal of Drug Metabolism and Pharmacokinetics 4/2012 Zur Ausgabe